Stocks › RGEN
REPLIGEN CORP
RGEN·Nasdaq·
United States·USD
United States·USD$174.86
-14.64 (-7.73%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
RGEN
REPLIGEN CORP · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGENS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RGEN by members of U.S. Congress · 8 on record · 3 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 31, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Aug 13, 2025 | Jun 17, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jul 22, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jun 11, 2025 | Filing ↗ |
 Jefferson ShreveHouse · R · IN |
RGENREPLIGEN CORP · Stock |
Sale $15,001 - $50,000 |
May 8, 2025 | Apr 7, 2025 | Filing ↗ |
 Ro KhannaHouse · D · CA |
RGENREPLIGEN CORP · Common Stock |
Sale $1,001 - $15,000 |
Jan 7, 2022 | Dec 14, 2021 | Filing ↗ |
Whale Activity
Position changes in RGEN reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 1.0M | $196.2M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RGEN insiders, by quarter · Form 4
Recent Insider Transactions
1,091 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Loeillot OlivierChief Executive Officer · Director | Sale | −4,202 | $190.00 | $798K | Oct 5, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −1,333 | $178.75 | $238K | Oct 5, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −8,404 | $190.00 | $1.6M | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −4,542 | $190.00 | $863K | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −5,426 | $180.00 | $977K | Sep 21, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −3,035 | $165.90 | $504K | Sep 4, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −5,426 | $180.00 | $977K | Aug 20, 2026 | Form 4 ↗ |
| Garland Jason KCFO | Sale | −530 | $150.00 | $80K | Jul 16, 2026 | Form 4 ↗ |
| Garland Jason KCFO | Sale | −733 | $145.00 | $106K | Jun 25, 2026 | Form 4 ↗ |
| Konstantinov KonstantinDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Madaus Martin DDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| EGLINTON MANNER CARRIEDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| MUIR GLENN PDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Mhatre RohinDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Pax MargaretDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| DAWES KAREN ADirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| BARTHELEMY NICOLASDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| MUIR GLENN PDirector | Option exercise | +2,434 | $38.76 | $94K | May 7, 2026 | Form 4 ↗ |
| Douglass Brian RobbCHIEF PRODUCT OFFICER | Tax withholding | −334 | $126.43 | $42K | May 7, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −3,832 | $140.00 | $536K | Apr 21, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RGEN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 1.8M | $247.6M | 0.20% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $232.3M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $167.7M | 0.09% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963.0K | $131.4M | 0.89% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund MFS Series Trust IV | 862.4K | $106.9M | 0.78% | May 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 709.0K | $96.7M | 0.21% | Jun 30, 2026 |
| Wasatch Core Growth Fund WASATCH FUNDS TRUST | 674.0K | $92.0M | 3.08% | Jun 30, 2026 |
| T. Rowe Price All-Cap Opportunities Fund T. Rowe Price All-Cap Opportunities Fund, Inc. | 748.5K | $88.2M | 0.61% | Mar 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 631.9K | $86.2M | 3.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 619.2K | $84.5M | 0.91% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list RGEN's shares (CUSIP 759916109), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming REPLIGEN CORP as client
No lobbying filings found naming REPLIGEN CORP as the client.
Government Contracts
Federal awards to repligen · USAspending
$204KAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming REPLIGEN CORP
No USPTO patent applications found for REPLIGEN CORP.
Annual Financials
From RGEN's 10-K filings · XBRL
No annual XBRL figures on record for RGEN. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in RGEN's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02Officer / director changeSep 15, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.02, 7.01, 8.01, 9.01Material agreement · Results of operations · Reg FD disclosureJul 22, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 15, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About REPLIGEN CORP
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersWALTHAM, MA
IncorporatedDE
SEC CIK0000730272 ↗